The Cdc25 dual-speci®city phosphatases control progression through the eukaryotic cell division cycle by activating cyclin-dependent kinases. Cdc25 A regulates entry into S-phase by dephosphorylating Cdk2, it cooperates with activated oncogenes in inducing transformation and is overexpressed in several human tumors. DNA damage or DNA replication blocks induce phosphorylation of Cdc25 A and its subsequent degradation via the ubiquitin±proteasome pathway. Here we have investigated the regulation of Cdc25 A in the cell cycle. We found that Cdc25 A degradation during mitotic exit and in early G 1 is mediated by the anaphase-promoting complex or cyclosome (APC/ C) Cdh1 ligase, and that a KEN-box motif in the N-terminus of the protein is required for its targeted degradation. Interestingly, the KEN-box mutated protein remains unstable in interphase and upon ionizing radiation exposure. Moreover, SCF (Skp1/ Cullin/F-box) inactivation using an interfering Cul1 mutant accumulates and stabilizes Cdc25 A. The presence of Cul1 and Skp1 in Cdc25 A immunocomplexes suggests a direct involvement of SCF in Cdc25 A degradation during interphase. We propose that a dual mechanism of regulated degradation allows for ®ne tuning of Cdc25 A abundance in response to cell environment.
Introduction
Orderly progression through the cell division cycle in all eukaryotic cells requires the periodic activation of cyclindependent kinases (Cdks) (Miller and Cross, 2001 ). The activation state of Cdks is regulated by association with cyclin and CDK-inhibitor (Cki) subunits. Furthermore, phosphorylation within the so-called`activation loop' controls enzyme activity, and reversible phosphorylation on residues located near the ATP-binding site of the protein provides a further mechanism for immediate inactivation/re-activation of Cdks (Sherr and Roberts, 1999) . In mammalian cells, Cdc2/cyclin B1 is kept inactive by phosphorylation on Thr14 and Tyr15 during interphase, and is suddenly activated at the end of G 2 to lead cells into mitosis (Krek and Nigg, 1991; Norbury et al., 1991) . Moreover, inhibitory tyrosine phosphorylation of Cdc2 in response to DNA damage underlies the G 2 /M checkpoint (Blasina et al., 1997) . A failure to dephosphorylate analogous residues in Cdk2 keeps the kinase inactive upon induction of DNA damage or inhibition of DNA replication (Mailand et al., 2000; Molinari et al., 2000) . Dephosphorylation of these critical threonine and tyrosine residues is mediated by the Cdc25 dual-speci®city protein phosphatases. In mammalian cells, Cdc25 C dephosphorylates Cdc2/cyclin B1 (Strausfeld et al., 1994) and is essential for progression through the G 2 /M phase of the cell cycle (Sadhu et al., 1990; Heald et al., 1993) . Two related enzymes, Cdc25 A and Cdc25 B, have been subsequently identi®ed (Galaktionov and Beach, 1991) and shown to be deregulated in cancer (Galaktionov et al., 1995; Gasparotto et al., 1997; Hernandez et al., 1998; Wu et al., 1998) . Cdc25 A is required for DNA replication and entry into S-phase, its primary substrate being Cdk2 (Hoffmann et al., 1994; Jinno et al., 1994; Blomberg and Hoffmann, 1999) . Cdc25 A is a transcriptional target of c-Myc and E2F, and its RNA and protein levels increase as cells are stimulated to enter the cycle from quiescence (Galaktionov et al., 1996; Blomberg and Hoffmann, 1999; Vigo et al., 1999) . On the contrary, Cdc25 B appears to play a role in mitosis with a different timing in respect to Cdc25 C (Karlsson et al., 1999) . Cdc25 A is activated by phosphorylation (Hoffmann et al., 1994) and its abundance is regulated by the ubiquitin±proteasome pathway. Degradation of Cdc25 A via the ubiquitin±proteasome pathway occurs in response to inhibition of DNA replication or induction of DNA damage (Mailand et al., 2000; Molinari et al., 2000) . Ubiquitylation and subsequent degradation via the proteasome represent a fundamental mechanism for regulating protein abundance through an irreversible mechanism (Pickart, 2001; Harper, 2002) . The system operates by transferring ubiquitin moieties to protein substrates via a series of enzymatic reactions catalyzed by E1, E2 and E3 enzymes, the latter being the determinant for target selectivity and timing of degradation (Hochstrasser, 1996; Hershko, 1997) . The E3 family comprises HECT domain E3 enzymes and RING ®nger E3 ubiquitin ligases, among which are the anaphase-promoting complex or cyclosome (APC/C) and the Skp1/Cullin/F-box (SCF) protein complexes (for a review, see Jackson et al., 2000) .
While APC is mainly involved in controlling the abundance of mitotic regulators (Zachariae and Nasmyth, 1999) , SCF ligases have a broader function in many physiological processes by ubiquitylating proteins involved in cell cycle regulation and signal transduction Dual mode of degradation of Cdc25 A phosphatase The EMBO Journal Vol. 21 No. 18 pp. 4875±4884, 2002 ã European Molecular Biology Organization (Peters, 1998; Koepp et al., 1999; Harper, 2002) . Speci®c timing of substrate degradation by the APC/C complex depends upon the targeting subunit with which they interact. Two such adaptors have been identi®ed, Cdc20 and Cdh1 (Visintin et al., 1997; Kramer et al., 2000) . It is widely assumed that the destruction of APC/C targets in metaphase and anaphase is regulated by Cdc20, while in late mitosis and early G 1 APC/C is associated to and activated by Cdh1 (Kramer et al., 2000) . APC/C Cdc20 recognizes destruction box (D-box)-containing proteins (King et al., 1996) , while APC/C Cdh1 recognizes proteins containing either a D-box or a KEN-box motif (Petersen et al., 2000; P¯eger and Kirschner, 2000; P¯eger et al., 2001) .
Recruitment of substrates to the SCF complex occurs via a protein-binding domain within the F-box protein subunit. At least three classes of F-box proteins have been described, depending upon the presence of WD-40, leucine-rich repeats or other protein-binding domains (Cenciarelli et al., 1999; Winston et al., 1999) . F-box proteins interact via the F-box motif with the Skp1 subunit, which can bridge the F-box to the cullin (Patton et al., 1998) , which in turn serves as a scaffold to bring the RING ®nger protein to the substrate (Tan et al., 1999) . Speci®city of SCF interaction with substrates is due to F-box protein recruitment and is generally mediated by phosphorylation events on target proteins (Jackson et al., 2000; Harper, 2002) .
We decided to investigate whether APC and SCF may play a role in the degradation of Cdc25 A. Here, we demonstrate that human Cdc25 A is a late mitotic target of the APC/C Cdh1 and that its recognition by the E3 ubiquitin ligase complex relies upon the presence of a KEN-box motif. Nevertheless, Cdc25 A KEN mutant is still unstable throughout interphase and upon DNA damage. We demonstrate that the abundance of the protein can be affected by overexpressing a mutated Cul1 protein that fails to interact with Roc1 and UBC proteins. Moreover, we detected Cul1 and Skp1 in Cdc25 A immunocomplexes, thus providing evidence that SCF may be involved in Cdc25 A degradation. In addition to being an APC/C target, Cdc25 A might therefore either be a substrate of SCF or be degraded through a mechanism that itself depends on SCF.
Results

Cdc25 A stabilization in mitotic cells
We have previously shown that in human cells the levels of Cdc25 A are periodically regulated in the cell cycle with a continuous increase in abundance from late G 1 until mitosis (Molinari et al., 2000) . In Figure 1A , we show that Cdc25 A levels rapidly decreased as HeLa cells were released into the cell cycle from a nocodazole-induced metaphase arrest. The protein became rapidly undetectable, to be induced again as cells approached the next Sphase. Decrease in Cdc25 A is evident before completion of mitosis and cytokinesis as assessed by¯ow cytometry, and paralleled that of cyclin B1. To assess whether the accumulation of Cdc25 A in prometaphase cells was due to a stabilization of the protein, we tested whether its halflife was increased in nocodazole-arrested cells compared with an asynchronous cell population ( Figure 1B ). Prometaphase cells, obtained by a 16-h nocodazole treatment, were incubated further with the protein synthesis inhibitor cycloheximide and followed over a period of 120 min in parallel with an asynchronous cell population ( Figure 1B) . Furthermore, to address the question of whether the reduction in the quantity of Cdc25 A upon release from mitotic arrest was due to a decrease in protein stability, we compared the half-life of the protein in cells upon nocodazole arrest and upon mitotic exit ( Figure 1C) . A cell population enriched in early G 1 -phase was obtained by releasing prometaphase nocodazole-arrested cells in fresh medium for 1 h, and analyzed for protein stability by treatment with cycloheximide over a period of 60 min ( Figure 1C ). Both in asynchronously growing cells and in cells exiting mitosis, Cdc25 A was unstable, with an estimated half-life of <10 min. In prometaphase-arrested cells, on the other hand, the half-life of Cdc25 A was clearly prolonged (Figure 1B and C) . Expression levels of cyclin B1 and cyclin A were followed in prometaphase and in asynchronous cells, and are shown in Figure 1B . Cyclin A levels were higher in asynchronous cells compared with prometaphase-arrested cells, while cyclin B1 behaved in the opposite way, thus suggesting that during mitosis Cdc25 A, like cyclin B1, is degraded later than cyclin A, and after the transition from metaphase to anaphase (see Clute and Pines, 1999; Geley et al., 2001) .
Data obtained with nocodazole-arrested cells were con®rmed by an alternative strategy of cell synchronization ( Figure 1D ). HeLa cells were arrested in early S-phase by double thymidine treatment and released for 8 and 12 h into next G 2 -and G 1 -phases, respectively. Cells were analyzed further for Cdc25 A stability by treatment with cycloheximide for the indicated times (in minutes). A cell population enriched in G 2 -phase ( Figure 1D , middle panel) showed an increased steady-state level of Cdc25 A compared with early S-phase (left panel) and G 1 -phase cells (right panel, compare`0' time points). Moreover, no signi®cant degradation of Cdc25 A was observed in G 2 , whereas a very rapid turnover of Cdc25 A was evident in early S-and G 1 -phases. Altogether, these observations suggest that degradation of Cdc25 A, in cells that exit mitosis and in early G 1 , is compatible with an involvement of the APC/C complex.
Cdc25 A degradation is APC/C Cdh1 dependent
The fact that oscillations in Cdc25 A levels parallel those in cyclin B1 suggests that Cdc25 A, like cyclin B1, may be degraded by the APC. To assess which activator of the APC/C might be involved in Cdc25 A degradation, we transfected asynchronous cells with wild-type Cdc25 A, along with either Cdh1 or Cdc20, and tested whether this affected Cdc25 A accumulation ( Figure 2A ). We noticed that Cdh1, but not Cdc20 overexpression, resulted in a signi®cant decrease in the steady-state level of the protein.
The decrease in the amount of Cdc25 A induced by Cdh1 was prevented by the addition of the proteasome inhibitor MG132, suggesting that Cdh1-dependent degradation of Cdc25 A occurs through the ubiquitin±proteasome pathway and that Cdh1 expression might be rate limiting for the degradation of Cdc25 A. It should be mentioned that this phenomenon does not re¯ect an indirect effect on cell cycle position, since neither Cdh1 nor Cdc20 overexpression caused major changes in cell cycle distribution over the course of transient transfection (not shown).
To test further the hypothesis that Cdh1 is required for the degradation of Cdc25 A, we attempted to inhibit the endogenous expression of either Cdh1 or Cdc20 by transfecting HeLa cells with small interfering dsRNAs corresponding to different portions of either the CDH1 or the CDC20 gene (Elbashir et al., 2001) . Transfection with two distinct siRNAs directed at CDH1 resulted in reduced amounts of the protein and increased levels of endogenous Regulation of Cdc25 A by both APC/C and SCF Cdc25 A ( Figure 2B ). Even a limited decrease of Cdh1 levels (oligo B) correlated with accumulation of Cdc25 A ( Figure 2B ). In contrast, inhibition of CDC20 expression did not correlate with Cdc25 A accumulation, thus con®rming that Cdh1 is speci®cally required for Cdc25 A degradation.
APC/C Cdh1 -mediated degradation of Cdc25 A requires an intact KEN-box motif A preliminary analysis of the stability of Cdc25 A deletion mutants indicated that a region between amino acids 51 and 170 was required for the degradation of the protein induced by Cdh1 ( Figure 3A ). Given the high speci®city of substrate recognition by APC/C complexes, we searched for the presence of sequence motifs known to target proteins to either Cdc20 or Cdh1: a nine amino acid D-box, ®rst identi®ed in cyclin B1 (Glotzer et al., 1991) , and a KEN-box, responsible for the destruction of the APC/C regulator Cdc20 (P¯eger and Kirschner, 2000) . By alignment with known destruction motifs of APC/C target proteins, we identi®ed one putative D-box (RXXL motif) and two KEN-box motifs (Figure 3B and C, upper panel) in the region between amino acids 51 and 170. Interestingly, the region containing the KEN2 motif is conserved among Cdc25 family proteins of different species ( Figure 3C , lower panel) and, most importantly, this same motif is involved in the degradation of Cdc25 C induced by arsenite (Chen et al., 2002) . We mutated these motifs individually or in combination ( Figure 3D ) and assessed whether comparable amounts of recombinant proteins were equally sensitive to Cdh1 overexpression. Among the generated mutants, the KEN2-mutated Cdc25 A was less sensitive to the presence of overexpressed Cdh1 and this phenomenon was observed also for the double KEN1/KEN2 mutant ( Figure 3D ). Cdc25 A is ubiquitylated by APC/C Cdh1 in vitro To assess whether Cdc25 A is a substrate of the APC/C ligase, in vitro ubiquitylation assays, using puri®ed cyclosome from HeLa cells and recombinant Cdh1 or Cdc20 proteins, were performed (Golan et al., 2002) . As shown in Figure 4A (left panel), Cdc25 A was polyubiquitylated by dephosphorylated APC/C in the presence of Cdh1, but not by phosphorylated APC/C activated by Cdc20. As a control, the cyclosome preparations were tested for ubiquitin ligase activity on a 125 I-labeled N-terminal fragment of cyclin B and results are shown in Figure 4A (right panel). In line with the ®ndings described in Figure 3 , the KEN2 and the double KEN1/ KEN2 mutants of Cdc25 A were not ubiquitylated in vitro, thus con®rming that Cdc25 A is a speci®c substrate of the APC/C Cdh1 ligase ( Figure 4B ). The KEN2 motif is required for APC/C Cdh1 -dependent degradation upon exit from mitosis We next assayed the stability of wild-type and KEN2-mutated Cdc25 A during mitotic exit and in early G 1 -phase, stages of the cell cycle at which APC/C Cdh1 is active. Cells transfected with constructs encoding the wild-type or the KEN2-mutated proteins were enriched in G 2 -phase according to the experimental scheme illustrated in Figure 5A . A fraction enriched in rounded, mitotic cells was released into the cell cycle and samples were collected at different time points. The levels of Cdc25 A were monitored by immunoblotting with an anti-Flag antibody. The KEN2 mutant was resistant to degradation under conditions in which both wild-type Cdc25 A and cyclin B1 were rapidly degraded ( Figure 5B ). These results con®rmed that Cdc25 A is degraded upon exit from mitosis in an APC/C Cdh1 -dependent fashion.
We noticed that while the KEN2-mutated Cdc25 A was stable in cells exiting mitosis, it remained intrinsically unstable in interphase cells. We transfected asynchronous cells with plasmids encoding wild-type, KEN2-, double KEN1/KEN2-and DEX2-mutated Cdc25 A to assess their protein stability. All recombinant proteins were rapidly degraded upon cycloheximide treatment and the addition of the proteasome inhibitor MG132 prevented this effect ( Figure 6A ). This observation suggests that a ubiquitin± proteasome pathway independent from the APC/C Cdh1 may be responsible for the rapid turnover of Cdc25 A during interphase.
As demonstrated by Falck et al. (2001) , wild-type Cdc25 A undergoes ionizing radiation (IR)-induced degradation that is partially rescued by substitution of Ser123 with Ala, thus indicating that phosphorylation of Cdc25 A on Ser123 may represent a signal for rapid destruction of the protein upon DNA damage. We reasoned that if the KEN motif is involved in IR-induced degradation of Cdc25 A, its mutation may result in increased protein stability upon IR exposure. We transfected asynchronous cells with plasmids encoding wildtype, KEN2-and S123A-mutated proteins, and assessed their stability upon IR-induced DNA damage. As shown in Figure 6B , both wild-type and KEN2-mutated proteins were affected in a comparable fashion by IR exposure, while the degradation of the control S123A-mutated protein was substantially delayed.
The SCF complex is involved in Cdc25 A degradation Degradation mechanisms other than those dependent upon the APC/C complex might therefore be responsible for the rapid turnover of Cdc25 A during interphase and IRinduced DNA damage. The SCF E3 ubiquitin ligases, which are also responsible for degradation of cell cycle regulators, are good candidates. To test the possible involvement of SCF in mediating Cdc25 A degradation in interphase, we made use of an N-terminal Cul1 mutant, Cul1(1±452) that interferes with the degradation of SCF substrates (Wu et al., 2000) . The Cul1 mutant lacks the Roc1/UBC binding region, and whilst retaining its ability to bind to F-box proteins through Skp1 prevents substrates (A) Scheme of the protocol applied to HeLa cells to obtain a transfected population released into the cell cycle after a partial synchronization in G 2 /M. Cells were enriched in early S-phase by a thymidinetreatment (12 h). During the last 3 h of the release period in drug-free medium (8 h), cells were transfected with lipofectamine and treated further with thymidine for 12 h. An 8-h release period in drug-free medium followed S-phase synchronization. When most of the cells detached from the plate with a rounded phenotype, indicating a G 2 /M enrichment, they were harvested and re-plated to be collected at the indicated time points. (B) Extracts were prepared from cells transfected either with Flag-tagged wild-type or K2 mut Cdc25 A proteins according to the scheme shown in (A). Flag-Cdc25 A and cyclin B1 were detected by immunoblotting with anti-Flag and anti-cyclin B1 antibodies, respectively. Cell cycle pro®les were determined by¯ow cytometry and reported in the table as percentages of cells in different phases.
Regulation of Cdc25 A by both APC/C and SCF from being ubiquitylated and subsequently degraded. Upon Flag-Cul1(1±452) expression, both the endogenous Cdc25 A and the protein expressed upon transient transfection substantially increased in abundance ( Figure 7A ). The same was observed for p27, a known substrate of the SCF Skp2 complex (Carrano et al., 1999) , but not for cyclin B1, a substrate of APC/C. These observations underlie the speci®city of action of Cul1 and rule out the possibility that Cul1(1±452) interferes with the function of the APC/C complex.
The accumulation of transfected Cdc25 A upon Cul1(1±452) overexpression was the result of protein stabilization as shown by cycloheximide addition ( Figure 7B ). The effect of Cul1(1±452) overexpression was observed even on the KEN2-mutated protein, thus allowing us to conclude that protein signatures other than the KEN-box motif are likely to be involved in the degradation of Cdc25 A during interphase. To substantiate this ®nding further, we assayed whether known members of SCF complexes could interact with Cdc25 A. Both Cul1 and Skp1 were identi®ed in Cdc25 A immunoprecipitations, a result that demonstrated the existence of a physical interaction between members of the SCF complex and Cdc25 A ( Figure 7C ).
Discussion
In previous work we demonstrated that the Cdc25 A phosphatase is rapidly degraded when cells are treated with hydroxyurea or other DNA synthesis inhibitors. We could demonstrate that Cdc25 A is ubiquitylated and degraded via the proteasome pathway and that its half-life is severely shortened in response to a block in DNA synthesis (Molinari et al., 2000) . Similar results were obtained by Mailand et al. (2000) , who showed that Cdc25 A disappears in response to DNA damage and that failure to degrade Cdc25 A results in unscheduled DNA synthesis (Falck et al., 2001) .
In this paper, we demonstrate that Cdc25 A is targeted for degradation by the APC/C ubiquitin ligase upon mitotic exit and that APC/C-dependent degradation of Cdc25 A requires a KEN-box motif. We also show that a KEN-box mutant of Cdc25 A remains unstable during interphase and upon DNA damage, and that interfering with SCF function appears to affect Cdc25 A degradation.
Cdc25 A is a late mitotic target of the APC/C complex Cdc25 A protein accumulates from G 1 until mitosis, to be degraded as cells enter the next cell cycle with similar kinetics to cyclin B1. The degradation of Cdc25 A is (B) Cells were transfected with Flag-tagged Cdc25 A, K2 mut and S123A mutants. Twenty-four hours post-transfection, cells were exposed to 10 Gy, and 1 h after irradiation were treated with cycloheximide for the indicated time points. Ectopic expression levels of wild-type and mutated proteins of Cdc25 A were detected by immunoblotting with anti-Flag antibody. mediated by the APC/C complex. More speci®cally, Cdh1, an activator of APC/C (P¯eger and Kirschner, 2000) , is rate limiting and is required for Cdc25 A regulation since its overexpression induces Cdc25 A degradation and its silencing results in Cdc25 A accumulation. The addition of a proteasome inhibitor to cells overexpressing Cdh1 prevents degradation of Cdc25 A, con®rming that Cdc25 A is lost due to proteasome-dependent turnover rather than to inhibition of transcription or translation. Identi®cation of a KEN-box motif in the N-terminal part of the protein provides con®rmation that Cdc25 A is a substrate of the APC/C Cdh1 complex both in vivo and in vitro. More speci®cally, we ®nd that the KEN2-mutated protein is insensitive to degradation upon mitotic exit and in early G 1 , when the APC/C Cdh1 complex is active (Kramer et al., 2000) .
Biological role of Cdc25 A at mitosis Until very recently it had been assumed that in mammalian cells, Cdc25 A was responsible solely for regulation of the cell cycle at the G 1 /S boundary, its primary substrate being the Cdk2 protein kinase (Hoffmann et al., 1994; Jinno et al., 1994; Blomberg and Hoffmann, 1999) . Since these experiments were performed in serum-starved cells that were released into the cycle from quiescence, by design they did not address the possible role of Cdc25 A in cellcycle transitions occurring beyond G 1 /S phase. Previous ®ndings had indeed shown that microinjection of antiCdc25 A antibodies in HeLa cells blocked cell division and resulted in the accumulation of cells with a mitoticlike phenotype (Galaktionov and Beach, 1991) . On the contrary, it is well proven that Cdc25 B and Cdc25 C cooperate with a concerted action at the G 2 /M phase transition, their main substrate being the mitotic kinase Cdc2/cyclin B (Gabrielli et al., 1996; Karlsson et al., 1999) .
Previous observations reporting the nuclear accumulation of Cdc25 A, and recent ®ndings of an increase in abundance of the protein in G 2 and M (this paper and Molinari et al., 2000) , raise the possibility that Cdc25 A may play a role in mitosis. These data should help our understanding of how mitosis could be triggered by a protein like Cdc25 C, whose localization is primarily cytoplasmic and that is poorly active unless phosphorylated by Cdc2/cyclin B (Heald et al., 1993) . Recent ®ndings demonstrate that Cdc25 C shuttles between the nucleus and the cytoplasm in a cell cycle-dependent manner, and that this mechanism may be required for a correct timing of mitotic induction (Takizawa and Morgan, 2000) . Yet, contrary to Cdc25 A and Cdc25 B, the Cdc25 C protein is detected at constant levels through the cell cycle (Gabrielli et al., 1996) . Our hypothesis is that Cdc25 A could act in a concerted manner with Cdc25 C and Cdc25 B to induce mitosis (Karlsson et al., 1999) . The existence of multiple control mechanisms that cooperate in preventing unscheduled mitosis is also suggested by the ®nding that overexpression of Cdc25 C does not completely override a DNA replication checkpoint (Karlsson et al., 1999) . On the contrary, in our previous work we showed that Cdc25 A overexpression can induce chromosome condensation and activation of mitotic events even in the presence of a DNA replication block (Molinari et al., 2000) . Work published by Heald et al. (1993) supported the notion that continued activation of the Wee1 protein kinase in interphase contributes to protect the nucleus from untimely initiation of mitotic events by Cdc25 phosphatase. While at that time it was thought that Cdc25 C was the only`mitotic phosphatase', the model proposed is still fully valid. Accumulation of Cdc25 A over time and up to a threshold level could very well represent the critical event required for triggering mitosis. The additional contribution of Cdc25 B and C could be required for signal ampli®cation or by the need to target speci®c subcellular loci.
Interphase degradation of Cdc25 A The observation that Cdc25 A remains almost undetectable until cells enter S-phase, and evidence that Cdc25 A is a target of the DNA damage-dependent intra-S-phase checkpoint (Falck et al., 2002) , suggest that in addition to the mitosis speci®c APC/C complex, other ubiquitin ligases may be responsible for its constitutive and induced degradation. Since the KEN2-mutated form of Cdc25 A is still unstable in interphase and in cells exposed to ionizing radiation, signal(s) other than the KEN2-box must be involved in these alternative pathways for Cdc25 A degradation. A good candidate E3 ubiquitin ligase is SCF, because of its involvement in multiple pathways Harper, 2002) .
Here we show that a dominant-negative mutant version of the Cul1 subunit, lacking the Roc1/UBC binding region (Wu et al., 2000) , is able to accumulate and stabilize Cdc25 A, possibly by sequestering the protein in a complex containing Skp1 and an unknown F-box protein. p27, a well known target of the SCF complex (Carrano et al., 1999) , also accumulates upon Cul1 mutant transfection. On the contrary, cyclin B1, a typical target of the APC/C complex, remains unaffected, thus con®rm-ing the speci®city of action of the Cul1 mutant. The existence of in vivo interactions between components of the SCF complex and Cdc25 A provides evidence that SCF is involved in Cdc25 A degradation, either directly or indirectly, perhaps through activation of a distinct ubiquitin ligase. We assume that the increase in Cdc25 A abundance upon transfection of the Cul1 mutant is due to the decreased rate of its degradation in interphase cells, and we have preliminary evidence that cells expressing the Cul1 mutant also fail to degrade Cdc25 A upon exposure to ionizing radiation. Yet, at present we cannot formally prove that a speci®c SCF ubiquitin ligase is responsible for Cdc25 A degradation, either in unperturbed or in perturbed cells.
Tight regulation of Cdc25 A abundance
We hypothesize that the intrinsic instability of Cdc25 A allows for tight regulation of cell progression through the cycle, by providing an emergency mechanism for immediate checkpoint activation. Mailand et al. (2000) demonstrated that DNA damaging events are able to immediately block cell cycle progression by inducing rapid degradation of Cdc25 A. Similarly, we have shown that a block in DNA replication will immediately trigger the inactivation of Cdc25 A with a rapid increase in Cdk2 tyrosine phosphorylation (Molinari et al., 2000) . Induction of Cdc25 A degradation, and consequent inhibition of Cdk2 activity, are events required to prevent DNA replication in the presence of DNA strand breaks or stalled replication, and to allow ef®cient DNA repair. Interference with these pathways abolishes checkpoint activation and may lead to genome instability (Mailand et al., 2000; Molinari et al., 2000; Falck et al., 2001) .
We have now demonstrated that two ubiquitin ligase complexes are involved in controlling the abundance of Cdc25 A. A failure to downregulate the levels of Cdc25 A may result in a delay in cell cycle checkpoint activation and could explain how Cdc25 A overexpression in cancer might contribute to genomic instability. The recent ®nding that cyclin E overexpression in human tumors is linked to a defect in an SCF-mediated degradation pathway is in line with this concept (Koepp et al., 2001) .
Further work will be required to test whether SCF-or APC-dependent mechanisms are involved in inducing Cdc25 A degradation in response to checkpoint(s) activation. Falck et al. (2001) have shown that Cdc25 A-S123A, a mutant protein that cannot be phosphorylated at Ser123 by the Chk2 protein kinase, undergoes a delayed degradation in response to ionizing radiation. This ®nding might suggest the existence of an F-box protein that selectively recognizes and binds to phosphorylated Cdc25 A at Ser123 under DNA damage, thus accelerating protein ubiquitylation and degradation. Nevertheless, the possible involvement of APC/C ubiquitin ligase cannot be completely excluded. Sudo et al. (2001) demonstrated that APC/C Cdh1 is activated in response to a G 2 -phase arrest induced by ionizing radiation. Moreover, recent ®ndings reported that arsenite-induced G 2 /M-phase cell cycle arrest is mediated by degradation of Cdc25 C through activation of an APC/C-dependent mechanism (Chen et al., 2002) . We are currently investigating the possibility that either APC/C, perhaps through a mechanism different from the one operating at mitotic exit, or SCF mediate the effects of checkpoint activation through induction of Cdc25 A degradation.
Materials and methods
Cell culture, cell synchronizations and treatments HeLa cells were grown at 37°C in a 5% CO 2 atmosphere in Dulbecco's modi®ed Eagle's medium (Euroclone) supplemented with 10% bovine calf serum (Hyclone) and 2 mM L-glutamine (Euroclone). The following protocols were used to obtain HeLa cells arrested at speci®c stages of the cell cycle. Cells were synchronized in metaphase by treatment with 0.05 mg/ml nocodazole for 16 h. Rounded cells were collected by gentle pipetting and released from drug-induced cell cycle block by washing three times with phosphate-buffered saline (PBS) and replating in drugfree medium. Cells were collected at different time points up to 12 h. Cells were synchronized in early S-phase by double thymidine treatment (2 mM) for 12 h, and released in drug-free medium for 8 and 12 h. Cell cycle position was monitored by¯ow cytometry.
To inhibit protein synthesis, cells were cultured in the presence of 10 mg/ml cycloheximide for the indicated time points. Inhibition of protein synthesis in metaphase-arrested cells was achieved as follows: cells were treated with 0.05 mg/ml nocodazole for 16 h, and rounded cells were collected by gentle pipetting and cultured further with 0.05 mg/ml nocodazole and 10 mg/ml cycloheximide for up to 120 min. Inhibition of protein synthesis in cells exiting mitosis was achieved as follows: nocodazole-arrested cells were released in drug-free medium for 1 h and cultured further with 10 mg/ml cycloheximide for up to 60 min.
To obtain transfected metaphase HeLa cells, the cells were ®rst cultured with 2 mM thymidine for 12 h, released from thymidine-induced early S-phase arrest by washing three times with PBS, and re-fed with fresh medium for up to 8 h. Cells were transfected with lipofectamine during the last 3 h of release before being further cultured with 2 mM thymidine for 12 h. Lipofectamine-transfected cells were released in drug-free medium until rounded cells detached from the plate. Exit from mitosis and entry into G 1 was achieved by re-plating rounded cells and harvesting them at various time points up to 3 h. Changes in cell cycle pro®le were monitored by¯ow cytometry. Inhibition of the proteasomemediated degradation was observed by culturing cells for up to 6 h in the presence of 5 mM MG132 (Biomol).
Plasmids and transfections
Flag-tagged constructs encoding full-length or truncated versions of Cdc25 A were generated as follows: the full-length cDNA for Cdc25 A was obtained as a PCR product from pRC-CMV-Cdc25 A and cloned into the EcoRV restriction site of pCDNA3.1-FlagA; the 51-CT mutant was generated by PvuII±XhoI digestion of the full-length¯agged construct and the insertion of the fragment into EcoRV±XhoI-digested FlagBplasmid; and the 170-CT was produced by BglII±XhoI digestion of the full-length¯agged construct and the insertion of the fragment into BamHI±XhoI-digested FlagB-plasmid. pCDNA3.1-Flag-Cdc25 A point mutants were generated using the QuikChange Site-directed Mutagenesis kit (Stratagene). The following amino acid changes were made: the KEN motifs at positions 95±97 and 141±143 were mutated into AAA, producing K1 mut and K2 mut , respectively; both KEN motifs were mutated into AAA in K1/K2 mut ; and in D2 mut , the D-box motif RGCL at position 157±160 was changed into AGCA. All constructs were veri®ed by DNA sequencing.
The constructs pCMV-HA-Cdh1, pCMV-HA-Cdc20 and pCMV-Myc-EGFP were described previously (Petersen et al., 2000) and were provided by K.Helin. PCR3.1-Flag-Cul1(1±452) has been provided by Z.-Q.Pan (Wu et al., 2000) .
Cells were transiently transfected using calcium phosphate coprecipitation and harvested 24 h post-transfection. To monitor for transfection ef®ciency and protein loading, 1 mg of pCMV-Myc-EGFP was included in each transfection. Where indicated, cells were transfected with Lipofectamine (Invitrogen, Life Technologies) according to the manufacturer's instructions.
RNA interference
RNA interference was performed essentially as described previously (Elbashir et al., 2001) . Single-strand oligos (20 mM; Dharmacon research, Inc.) were incubated in annealing buffer for 1 min at 90°C followed by 1 h at 37°C. Transfection of siRNAs for targeting endogenous genes was carried out using Oligofectamine (Invitrogen, Life Technologies) and cell extracts assayed for gene silencing 24 h after transfection. For CDH1 siRNA, oligo A corresponded to nucleotide sequence 5¢-AATGAGA-AGTCTCCCAGTCAG-3¢ and oligo B to sequence 5¢-AATCTGGTG-GACTGGTCGTCC-3¢. For CDC20 siRNA, oligo A corresponded to nucleotide sequence 5¢-AAACCTGGCGGTGACCGCTAT-3¢ and oligo B to sequence 5¢-AATGTGTGGCCTAGTGCTCCT-3¢.
Cell extraction and immunoblot analysis
Samples harvested at various time points were washed twice with PBS, resuspended in lysis buffer (50 mM Tris±HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% deoxycolate, 50 mM NaF, 1 mM Na 3 VO 4 , 1 mM EDTA, 1 mM dithiothreitol) supplemented with 1 mg/ml aprotinin, 1 mg/ ml leupeptin and 10 mM PMSF, and incubated on ice for 15 min. Samples were assayed for protein concentration using the Bradford method. Equal amounts of samples were resolved by SDS±PAGE and proteins were transferred onto nitrocellulose membranes. After blocking with 5% dry non-fat milk in Tris-buffered saline containing 0.05% Tween, membranes were incubated with primary antibodies and subsequently with peroxidase-conjugated secondary antibodies. Immunoreactive bands were visualized by enhanced chemiluminescence (Pharmacia) on autoradiography ®lms. For co-immunoprecipitation analysis, cells were transfected with 10 mg of pCDNA-Flag-cdc25 A. Supernatants derived from lysed cells were incubated with the anti-Flag af®nity gel (M2, Sigma) for 2 h at 4°C. The resin was washed ®ve times with lysis buffer, resuspended with Laemli buffer, boiled, and analyzed by SDS±PAGE and immunoblotting as described previously (Molinari et al., 2000) .
The following antibodies were used: anti-Cdc25 A (F6; Santa Cruz); anti-Flag (M2; Sigma); anti-cyclin B1 (GNS1; Santa Cruz); anti-cyclin A (H-432; Santa Cruz); anti-Myc (9E10; Santa Cruz); anti-HA (12CA5; Babco); anti-vinculin (Sigma); anti-Cullin (Zymed); and anti-Skp1 (H-163; Santa Cruz). Anti-Cdh1 and anti-Cdc20 monoclonal antibodies were provided by K.Helin.
In vitro ubiquitylation assay
Ubiquitin ligation was determined essentially as reported by Golan et al. (2002) , except that the 125 I-labeled N-terminal fragment of cyclin B was replaced by 35 S-labeled, in vitro-translated Cdc25 A. Preparations of APC/C that were either phosphorylated or not were obtained from HeLa cells as described previously, and 1 ml was used for the in vitro ubiquitylation reaction. His 6 -tagged Cdh1 and Cdc20 were produced by infection of Sf9 insect cells with baculovirus expressing the corresponding proteins, and puri®ed by nickel±agarose chromatography. Where indicated, Cdh1 or Cdc20 was supplemented at 1 mM.
